EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study

Kowser Miah iD, Jitendar Reddy, Pradeep Sharma iD, Ike Igwegbe iD, Simon Nelson, Caitlin Muldoon, Ronald Goldwater iD, Karthick Vishwanathan iD

Pharmacology Research & Perspectives · 2026

DOI: 10.1002/prp2.70321 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Kowser Miah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, CPSS, AstraZeneca, Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2, Cytochrome P-450 CYP1A2 Inhibitors, Fluvoxamine, Protein Kinase Inhibitors. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Savolitinib is an oral, potent, selective CNS‐penetrant MET‐tyrosine kinase inhibitor that in vitro studies indicate is metabolized by cytochrome P450 (CYP) enzymes, including CYP1A2, and by non‐CYP enzymes, such as aldehyde oxidase (AO). Savolitinib primary metabolites, M2 and M3, are formed mainly by CYP1A2 and AO, respectively. This Phase 1, open‐label study evaluated the impact of CYP1A2 inhibition by fluvoxamine on the pharmacokinetics of savolitinib and its metabolites in 16 healthy male volunteers. Volunteers received a single oral dose of 300 mg savolitinib and, following a ≥ 10‐day washout period, 50 mg twice‐daily oral fluvoxamine for 6 days, with a single oral dose of 300 mg savolitinib co‐administered on Day 5. Serial pharmacokinetic samples were collected during both study periods. Savolitinib, M2, and M3 were measured using high‐performance liquid chromatography with tandem mass spectrometry. Systemic exposure of savolitinib increased by approximately 2‐fold (maximum plasma concentration) and 3‐fold (area under the plasma concentration‐time curve from time 0 to infinity) when savolitinib was administered with fluvoxamine compared with savolitinib alone. Systemic exposure of M2 and M3 decreased and increased, respectively, when savolitinib was administered with vs. without fluvoxamine, while the ratio of M2/savolitinib was reduced and that of M3/savolitinib remained unchanged. These data suggest a significant drug–drug interaction between savolitinib and the strong CYP1A2 inhibitor, fluvoxamine, and that CYP1A2 is involved in the formation of M2, but not M3. No new safety concerns were observed when savolitinib was administered alone or with twice‐daily fluvoxamine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP1A2Cytochrome P-450 CYP1A2 InhibitorsFluvoxamineProtein Kinase InhibitorsPyrazinesTriazinesAdultHumansMaleYoung AdultAdministration, OralArea Under CurveDrug InteractionsHealthy VolunteersTandem Mass Spectrometry

Substanzen

CYP1A2 protein, humanCytochrome P-450 CYP1A2Cytochrome P-450 CYP1A2 InhibitorsFluvoxamineProtein Kinase Inhibitors1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazinePyrazinesTriazines

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, CPSS, AstraZeneca, Waltham, Massachusetts, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, CPSS, AstraZeneca, Cambridge, UK.
  • Global Clinical Program, AstraZeneca, Gaithersburg, Maryland, USA.
  • Patient Safety Oncology, AstraZeneca, Cambridge, UK.
  • Late Oncology Statistics, AstraZeneca, Cambridge, UK.
  • Early Phase Clinical Unit, Parexel, Baltimore, Maryland, USA.

ORCID-Profile: Kowser Miah, Pradeep Sharma, Ike Igwegbe, Ronald Goldwater, Karthick Vishwanathan

Förderung

  • AstraZeneca

Zitieren

APA

Miah, K., Reddy, J., Sharma, P., Igwegbe, I., Nelson, S., Muldoon, C., Goldwater, R., & Vishwanathan, K. (2026). Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70321

Vancouver

Miah K, Reddy J, Sharma P, Igwegbe I, Nelson S, Muldoon C, et al. Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70321

BibTeX
@article{Miah2026,
  author = {Miah, Kowser and Reddy, Jitendar and Sharma, Pradeep and Igwegbe, Ike and Nelson, Simon and Muldoon, Caitlin and Goldwater, Ronald and Vishwanathan, Karthick},
  title = {Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  doi = {10.1002/prp2.70321}
}
Kostenlos starten →